COVID-19 Update

July 22, 2020

Pending approval of the Pfizer and BioNTech mRNA-based vaccine candidate against SARS-COV-2, the companies will supply the US government with an initial 100 million doses.

July 21, 2020

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

July 21, 2020

The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.

July 21, 2020

The UK government has secured early access to 90 million COVID-19 vaccine doses from the BioNTech/Pfizer alliance and Valneva.

July 21, 2020

Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.

July 21, 2020

Study reports immune and T-cell response from CanSino COVID-19 vaccine candidate.

July 20, 2020

A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.

July 20, 2020

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

July 16, 2020

Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development.

July 15, 2020

Suppliers to the bio/pharma industry are sharing news about the business operations during the global COVID-19 pandemic. To view current information about the company’s business operations, click the company name.